Adiponectin expression in patients with inflammatory cardiomyopathy indicates favourable outcome and inflammation control.

AIMS Circulating adiponectin (APN) is an immunomodulatory, pro-angiogenic, and anti-apoptotic adipocytokine protecting against acute viral heart disease and preventing pathological remodelling after cardiac injury. The purpose of this study was to describe the regulation and effects of APN in patients with inflammatory cardiomyopathy (DCMi). METHODS AND RESULTS Adiponectin expression and outcome were assessed in 173 patients with DCMi, 30 patients with non-inflammatory DCM, and 30 controls. Mechanistic background of these findings was addressed in murine experimental autoimmune myocarditis (EAM), a model of human DCMi, and further elucidated in vitro. Adiponectin plasma concentrations were significantly higher in DCMi compared with DCM or controls, i.e. 6.8 ± 3.9 µg/mL vs. 5.4 ± 3.6 vs. 4.76 ± 2.5 µg/mL (P< 0.05, respectively) and correlated significantly with cardiac mononuclear infiltrates (CD3+: r(2)= 0.025, P= 0.038; CD45R0+: r(2)= 0.058, P= 0.018). At follow-up, DCMi patients with high APN levels showed significantly increased left ventricular ejection fraction improvement, decreased left ventricular end-diastolic diameter, and reduced cardiac inflammatory infiltrates compared with patients with low APN levels. A multivariate linear regression analysis implicated APN as an independent prognostic factor for inhibition of cardiac inflammation. In accordance with these findings in human DCMi, EAM mice exhibited elevated plasma APN. Adiponectin gene transfer led to significant downregulation of key inflammatory mediators promoting disease. Mechanistically, APN acted as a negative regulator of T cells by reducing antigen specific expansion (P< 0.01) and suppressed TNFα-mediated NFκB activation (P< 0.01) as well as release of reactive oxygen species in cardiomyocytes. CONCLUSION Our results implicate that APN acts as endogenously upregulated anti-inflammatory cytokine confining cardiac inflammation and progression in DCMi.

[1]  H. Schultheiss,et al.  Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. , 1999, Circulation.

[2]  G. Thiene,et al.  Immunosuppressive Therapy for Active Lymphocytic Myocarditis: Virological and Immunologic Profile of Responders Versus Nonresponders , 2003, Circulation.

[3]  Lukas Hunziker,et al.  Dendritic cell–induced autoimmune heart failure requires cooperation between adaptive and innate immunity , 2003, Nature Medicine.

[4]  N. Rose.  Infection, mimics, and autoimmune disease. , 2001, The Journal of clinical investigation.

[5]  B. DeGeorge,et al.  Cardioprotection afforded by NF-kappaB ablation is associated with activation of Akt in mice overexpressing TNF-alpha. , 2006, American journal of physiology. Heart and circulatory physiology.

[6]  David C. Young,et al.  Prevention of Cardiac Hypertrophy and Heart Failure by Silencing of NF-κB , 2008 .

[7]  Y. Sharabi,et al.  Circulating adiponectin concentrations in patients with congestive heart failure , 2006, Heart.

[8]  R. Chen,et al.  Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin. , 2008, International journal of cardiology.

[9]  J. K. Kim,et al.  Adiponectin Is a Negative Regulator of NK Cell Cytotoxicity1 , 2006, The Journal of Immunology.

[10]  Jan Frystyk,et al.  Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure , 2005, Circulation.

[11]  Michael Böhm,et al.  Predictors of Outcome in Patients With Suspected Myocarditis , 2008, Circulation.

[12]  T. Kanda,et al.  Oral Administration of Candesartan Improves the Survival of Mice with Viral Myocarditis through Modification of Cardiac Adiponectin Expression , 2007, Cardiovascular Drugs and Therapy.

[13]  S. Kihara,et al.  Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. , 2007, The Journal of clinical investigation.

[14]  I. Kallikazaros,et al.  To kill two birds with one stone: a pleurocentesis that also drained pericardial tamponade in a stubbed patient. , 2011, European heart journal.

[15]  E. Thiel,et al.  CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. , 2002, Blood.

[16]  D. Mann,et al.  Left Ventricular Remodeling in Transgenic Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor , 2001, Circulation.

[17]  A. Pfeiffer,et al.  Changes of adiponectin oligomer composition by moderate weight reduction. , 2005, Diabetes.

[18]  R. Piñeiro,et al.  Adiponectin is synthesized and secreted by human and murine cardiomyocytes , 2005, FEBS letters.

[19]  S. Kihara,et al.  Adiponectin protects against the development of systolic dysfunction following myocardial infarction. , 2007, Journal of molecular and cellular cardiology.

[20]  Heribert Schunkert,et al.  Left-ventricular dysfunction , 1998, The Lancet.

[21]  David C. Young,et al.  Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB. , 2008, Journal of molecular biology.

[22]  T. Kanda,et al.  Reduced-energy diet improves survival of obese KKAy mice with viral myocarditis: induction of cardiac adiponectin expression. , 2007, International journal of cardiology.

[23]  B. Stratmann,et al.  High molecular weight adiponectin correlates positively with myeloperoxidase in patients with type 2 diabetes mellitus. , 2008, Diabetes Research and Clinical Practice.

[24]  M. Kurabayashi,et al.  Impaired expression of cardiac adiponectin in leptin-deficient mice with viral myocarditis. , 2006, International heart journal.

[25]  S. Kihara,et al.  Adiponectin-mediated modulation of hypertrophic signals in the heart , 2004, Nature Medicine.

[26]  T. Funahashi,et al.  Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. , 2005, Cardiovascular research.

[27]  T. Kanda,et al.  Inhibition of cyclooxygenase-2 enhances myocardial damage in a mouse model of viral myocarditis. , 2005, Life sciences.

[28]  H. Sumino,et al.  Adiponectin Replacement Therapy Attenuates Myocardial Damage in Leptin-deficient Mice with Viral Myocarditis , 2005, The Journal of international medical research.

[29]  H. Fechner,et al.  Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. , 2006, European heart journal.

[30]  B. DeGeorge,et al.  Cardioprotection afforded by NF-κB ablation is associated with activation of Akt in mice overexpressing TNF-α , 2006 .

[31]  H. Katus,et al.  Critical Role for Monocyte Chemoattractant Protein-1 and Macrophage Inflammatory Protein-1α in Induction of Experimental Autoimmune Myocarditis and Effective Anti–Monocyte Chemoattractant Protein-1 Gene Therapy , 2005, Circulation.

[32]  B. Rovin,et al.  Chemokine induction by the adipocyte-derived cytokine adiponectin. , 2006, Clinical immunology.

[33]  M. Yacoub,et al.  Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates. , 2002, American heart journal.

[34]  C. Drevon,et al.  Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. , 2007, Endocrinology.

[35]  E. Ingelsson,et al.  Adiponectin and risk of congestive heart failure. , 2006, Journal of the American Medical Association (JAMA).

[36]  A. Angelini,et al.  A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. , 2007, European heart journal.

[37]  Paolo Fortina,et al.  Gene expression profiling during the transition to failure in TNF-alpha over-expressing mice demonstrates the development of autoimmune myocarditis. , 2004, Journal of molecular and cellular cardiology.

[38]  T. Mak,et al.  Low-molecular-weight tumor necrosis factor receptor p55 controls induction of autoimmune heart disease. , 1997, Circulation.

[39]  A. Demetris,et al.  Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. , 1997, Journal of cardiac failure.

[40]  J. McMurray,et al.  Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. , 2007, European heart journal.

[41]  R. Kandolf,et al.  High Prevalence of Viral Genomes and Multiple Viral Infections in the Myocardium of Adults With “Idiopathic” Left Ventricular Dysfunction , 2005, Circulation.

[42]  G. Fantuzzi.  Adiponectin and inflammation: consensus and controversy. , 2008, The Journal of allergy and clinical immunology.

[43]  Nader Rifai,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[44]  C. Angermann,et al.  Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. , 2003, Cardiovascular research.

[45]  H. Tilg,et al.  Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. , 2004, Biochemical and biophysical research communications.

[46]  Barry J Maron,et al.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.

[47]  U. Eriksson,et al.  CD11b+ Monocytes Abrogate Th17 CD4+ T Cell-Mediated Experimental Autoimmune Myocarditis1 , 2008, The Journal of Immunology.

[48]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[49]  Renu Virmani,et al.  A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology , 2022 .

[50]  I. Rodger,et al.  Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. , 1998, Circulation.